Li Yu-Jing, Chen Zhu
Department of Rheumatology and Immunology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Department of Rheumatology and Immunology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Lujiang Str 17, Hefei 230001, China.
Ther Adv Musculoskelet Dis. 2022 May 23;14:1759720X221100294. doi: 10.1177/1759720X221100294. eCollection 2022.
Rheumatoid arthritis (RA) is the most common immune-mediated inflammatory disease characterized by chronic synovitis that hardly resolves spontaneously. The current treatment of RA consists of nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, conventional disease-modifying antirheumatic drugs (cDMARDs), biologic and targeted synthetic DMARDs. Although the treat-to-target strategy has been intensively applied in the past decade, clinical unmet needs still exist since a substantial proportion of patients are refractory or even develop severe adverse effects to current therapies. In recent years, with the deeper understanding of immunopathogenesis of the disease, cell-based therapies have exhibited effective and promising interventions to RA. Several cell-based therapies, such as mesenchymal stem cells (MSC), adoptive transfer of regulatory T cells (Treg), and chimeric antigen receptor (CAR)-T cell therapy as well as their beneficial effects have been documented and verified so far. In this review, we summarize the current evidence and discuss the prospect as well as challenges for these three types of cellular therapies in RA.
类风湿关节炎（RA）是最常见的免疫介导性炎症疾病，其特征为慢性滑膜炎，几乎不会自发缓解。目前RA的治疗方法包括非甾体抗炎药（NSAIDs）、糖皮质激素、传统改善病情抗风湿药（cDMARDs）、生物制剂和靶向合成DMARDs。尽管在过去十年中强化应用了达标治疗策略，但由于相当一部分患者对当前治疗方法难治或甚至出现严重不良反应，临床未满足的需求仍然存在。近年来，随着对该疾病免疫发病机制的深入了解，基于细胞的疗法已展现出对RA有效且有前景的干预作用。目前，几种基于细胞的疗法，如间充质干细胞（MSC）、调节性T细胞（Treg）的过继转移、嵌合抗原受体（CAR）-T细胞疗法及其有益效果均已得到记录和验证。在本综述中，我们总结了当前证据，并讨论了这三种细胞疗法在RA中的前景以及挑战。
